Loading…
Loading…
you said you expect CGM to continue to track higher at about $1 billion a year
was hoping you could give a little more color on what's happening in The U. S. And outside The U. S.
walk through some of the trends you're seeing in each of those product lines, especially in diabetes
you were able to hold EPS for the full year even including the recently announced tariffs
speak to some of the key growth drivers and how we should think about the different business segments on the top line
I was wondering if you could just comment on how you think about your position in China
There's obviously a lot of moving pieces under the hood, wondering if you could tease out some of them
I saw you repurchased shares in the quarter. It's the first time in a while. Just wanted to hear the thought process
are you seeing any improvements in productivity? It could obviously be really helpful as we think about the upgrade cycle
the procedure volume was excellent in first quarter, and it's rare to see such a big raise after just one quarter
It feels like you're taking a worst-case approach here where you're putting all the negatives and there aren't a lot of offsets
Gary, you always give us a general state of the union on the health of the capital equipment environment around the world
you gave a lot of detail on the call about a midyear full launch and trade-in cycle. Would love to just get your qualitative comments